According to a new report by Univdatos Market Insights, PARP Inhibitors Market, is expected to reach USD 13835 Million in 2032 by growing at a CAGR of 12.9%. Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a revolutionary class of drugs in the treatment of cancer, majorly ovarian, breast, and prostate cancers. The demand for PARP inhibitors has grown subsequently in past few...